ORMP - オラメド・ファ―マシュ―ティカルズ (Oramed Pharmaceuticals Inc.)

ORMPのニュース

   Oramed Pharmaceuticals : Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients | MarketScreener  2020/09/15 12:26:04 MarketScreener
NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. , a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results… | September 15, 2020
   Oramed's Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients  2020/09/15 12:25:00 Benzinga
NEW YORK , Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results from a diabetes market survey conducted for Oramed by a third party research firm. The survey included qualitative interviews with healthcare providers as well as type 1 (T1D) and type 2 (T2D) diabetes patients regarding Oramed's lead oral insulin product, ORMD-0801, which is headed into a Phase III trial. Forty-one health care providers, including 22 endocrinologists and 19 primary care physicians, nurse practitioners, physician assistants and certified diabetes educators were surveyed. There was strong support among these health care providers for use of oral insulin with T2D patients early in the treatment process through a primary care physician before the need for injectable insulin and before the patient is moved to an endocrinologist for diabetes care.
   Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin  2020/07/15 12:55:00 Benzinga Feeds
NEW YORK , July 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the FDA provided positive feedback during the company's End of Phase 2 (EOP2) meeting for Oramed's oral insulin (ORMD-0801). Based on the FDA's feedback, Oramed intends to initiate two Phase 3 clinical trials following FDA review of those Phase 3 protocols, and nonclinical documents. The FDA outlined its expectations for design of the ORMD-0801 Phase 3 trials as well as submission of the Biologics License Application (BLA) that would follow successful trials. Oramed plans to conduct the two Phase 3 trials concurrently. Oramed's Chief Executive Nadav Kidron said, "We are very pleased with the results of our meeting with the FDA and look forward to submitting our finalized protocols for the Phase 3 trials to the FDA. Following successful Phase 3 trials, we would submit the BLA, which when approved would grant a full 12 years of marketing exclusivity for ORMD-0801.
   Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin  2020/06/15 12:25:00 PR Newswire
NEW YORK, June 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its pilot study of its oral insulin candidate ORMD-0801…
   Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June  2020/05/05 11:55:00 PR Newswire
NEW YORK, May 5, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will present during the 80th American Diabetes Association…
   Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin  2020/07/15 12:55:00 Benzinga Feeds
NEW YORK , July 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the FDA provided positive feedback during the company's End of Phase 2 (EOP2) meeting for Oramed's oral insulin (ORMD-0801). Based on the FDA's feedback, Oramed intends to initiate two Phase 3 clinical trials following FDA review of those Phase 3 protocols, and nonclinical documents. The FDA outlined its expectations for design of the ORMD-0801 Phase 3 trials as well as submission of the Biologics License Application (BLA) that would follow successful trials. Oramed plans to conduct the two Phase 3 trials concurrently. Oramed's Chief Executive Nadav Kidron said, "We are very pleased with the results of our meeting with the FDA and look forward to submitting our finalized protocols for the Phase 3 trials to the FDA. Following successful Phase 3 trials, we would submit the BLA, which when approved would grant a full 12 years of marketing exclusivity for ORMD-0801.
   Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin  2020/06/15 12:25:00 PR Newswire
NEW YORK, June 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its pilot study of its oral insulin candidate ORMD-0801…
   Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June  2020/05/05 11:55:00 PR Newswire
NEW YORK, May 5, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will present during the 80th American Diabetes Association…
   Oramed Pharmaceuticals Inc. Announces Proposed Public Offering of Common Stock  2020/02/26 21:05:00 PR Newswire
NEW YORK, Feb. 26, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that it intends to offer and sell shares of its common stock in an…
   Oramed Patent in Europe to be Granted for Oral Delivery of Proteins  2020/01/28 12:25:00 PR Newswire
NEW YORK, Jan. 28, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) and (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the European Patent Office has indicated its intent…
   Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin  2020/07/15 12:55:00 Benzinga Feeds
NEW YORK , July 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the FDA provided positive feedback during the company's End of Phase 2 (EOP2) meeting for Oramed's oral insulin (ORMD-0801). Based on the FDA's feedback, Oramed intends to initiate two Phase 3 clinical trials following FDA review of those Phase 3 protocols, and nonclinical documents. The FDA outlined its expectations for design of the ORMD-0801 Phase 3 trials as well as submission of the Biologics License Application (BLA) that would follow successful trials. Oramed plans to conduct the two Phase 3 trials concurrently. Oramed's Chief Executive Nadav Kidron said, "We are very pleased with the results of our meeting with the FDA and look forward to submitting our finalized protocols for the Phase 3 trials to the FDA. Following successful Phase 3 trials, we would submit the BLA, which when approved would grant a full 12 years of marketing exclusivity for ORMD-0801.
   Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin  2020/06/15 12:25:00 PR Newswire
NEW YORK, June 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its pilot study of its oral insulin candidate ORMD-0801…
   Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June  2020/05/05 11:55:00 PR Newswire
NEW YORK, May 5, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will present during the 80th American Diabetes Association…
   Oramed Pharmaceuticals Inc. Announces Proposed Public Offering of Common Stock  2020/02/26 21:05:00 PR Newswire
NEW YORK, Feb. 26, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that it intends to offer and sell shares of its common stock in an…
   Oramed Patent in Europe to be Granted for Oral Delivery of Proteins  2020/01/28 12:25:00 PR Newswire
NEW YORK, Jan. 28, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) and (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the European Patent Office has indicated its intent…

calendar